Table 2. Pharmacokinetic and cytotoxicity properties.
Drug | Anisomycin | Prodigiosin | Obatoclax | Nithiamide |
---|---|---|---|---|
in vivo data | ||||
Animal | rat | mouse | mouse | mouse |
Toxicity | LD50: 72mg/kg (oral) 1 | LD50: 18mg/kg (ip) 2 | >5mg/kg (IV) 3 | LD50: 300mg/kg (ip) 4 |
Cmax in μM | 0.01 (150mg/kg subQ) 5 | na | 0.24 (4.8mg/kg IV) 6 | na |
Cytotox (CC50) | ||||
HepG2 | 0.39μM | 0.21μM | 0.21μM | no activity |
HEK293 | 0.08μM | 0.13μM | 0.8μM | no activity |
MDCK | na | no activity 7 | 1.4μM 8 | na |
PBMCs | na | 241μM 9 | >4μM 3 | na |
Vero | 45μM 10 | na | 6.6μM 11 | na |
CHO | na | na | na | no activity 12 |
Huh-7 | 2.4μM 13 | na | 0.38μM 14 | na |
A549 | no activity 15 | na | 9.9μM 16 | na |
hFF-1 | >25μM | 0.14μM | 0.11μM | no activity |
LD50 and Cmax for published animal studies, and a selection of publicly available cytotoxicity data for each compound are shown. Route of administration and dosage in parenthesis. 'na' indicates that no data was available. Results for HepG2 and HEK293 cytotoxicity from Calibr (reframedb.org). Cytotoxicity against human foreskin fibroblast cells (hFF-1) was determined as mentioned in methods. Other data are as follows: 1. [24]; 2. [25]; 3. [26] Truedel 2007; 4. [27]; 5. [28]; 6. [29]; 7. [30]; 8. [31]; 9. [32]; 10. [33]; 11. [34]; 12. [35]; 13. [36] (pubchem AID:449705); 14. [37] (pubchem AID:742238); 15. [38] (pubchem AID:720523); 16. [39]